Robert F. Williamson III Purchases 38,145 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Robert F. Williamson III purchased 38,145 shares of the business's stock in a transaction dated Monday, March 31st. The stock was bought at an average price of $2.14 per share, with a total value of $81,630.30. Following the acquisition, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This represents a 53.85 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX traded down $0.16 during midday trading on Friday, reaching $1.80. The company's stock had a trading volume of 1,189,656 shares, compared to its average volume of 1,013,026. The business has a 50 day moving average price of $2.77 and a 200 day moving average price of $5.91. Perspective Therapeutics, Inc. has a 1 year low of $1.79 and a 1 year high of $19.05.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its position in Perspective Therapeutics by 8.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company's stock worth $274,000 after purchasing an additional 1,672 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Perspective Therapeutics by 5.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company's stock worth $783,000 after buying an additional 3,211 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Perspective Therapeutics by 7.4% during the 4th quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company's stock worth $163,000 after buying an additional 3,529 shares during the last quarter. Rhumbline Advisers raised its position in shares of Perspective Therapeutics by 4.5% in the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company's stock worth $303,000 after buying an additional 4,075 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Perspective Therapeutics by 3.4% in the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company's stock valued at $458,000 after acquiring an additional 4,693 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Royal Bank of Canada dropped their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Scotiabank initiated coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Monday, March 31st. Wedbush restated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $14.44.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.